Literature DB >> 35700010

Reference-Adjusted Loss in Life Expectancy for Population-Based Cancer Patient Survival Comparisons-with an Application to Colon Cancer in Sweden.

Therese M-L Andersson1, Mark J Rutherford2, Bjørn Møller3, Paul C Lambert1,2, Tor Åge Myklebust3.   

Abstract

BACKGROUND: The loss in life expectancy, LLE, is defined as the difference in life expectancy between patients with cancer and that of the general population. It is a useful measure for summarizing the impact of a cancer diagnosis on an individual's life expectancy. However, it is less useful for making comparisons of cancer survival across groups or over time, because the LLE is influenced by both mortality due to cancer and other causes and the life expectancy in the general population.
METHODS: We present an approach for making LLE estimates comparable across groups and over time by using reference expected mortality rates with flexible parametric relative survival models. The approach is illustrated by estimating temporal trends in LLE of patients with colon cancer in Sweden.
RESULTS: The life expectancy of Swedish patients with colon cancer has improved, but the LLE has not decreased to the same extent because the life expectancy in the general population has also increased. When using a fixed population and other-cause mortality, that is, a reference-adjusted approach, the LLE decreases over time. For example, using 2010 mortality rates as the reference, the LLE for females diagnosed at age 65 decreased from 11.3 if diagnosed in 1976 to 7.2 if diagnosed in 2010, and from 3.9 to 1.9 years for women 85 years old at diagnosis.
CONCLUSIONS: The reference-adjusted LLE is useful for making comparisons across calendar time, or groups, because differences in other-cause mortality are removed. IMPACT: The reference-adjusted approach enhances the use of LLE as a comparative measure. ©2022 The Authors; Published by the American Association for Cancer Research.

Entities:  

Mesh:

Year:  2022        PMID: 35700010      PMCID: PMC9437567          DOI: 10.1158/1055-9965.EPI-22-0137

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.090


  25 in total

1.  Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population.

Authors:  Hannah Bower; Magnus Björkholm; Paul W Dickman; Martin Höglund; Paul C Lambert; Therese M-L Andersson
Journal:  J Clin Oncol       Date:  2016-06-20       Impact factor: 44.544

2.  Estimating the crude probability of death due to cancer and other causes using relative survival models.

Authors:  P C Lambert; P W Dickman; C P Nelson; P Royston
Journal:  Stat Med       Date:  2010-03-30       Impact factor: 2.373

3.  Reference-adjusted and standardized all-cause and crude probabilities as an alternative to net survival in population-based cancer studies.

Authors:  Paul C Lambert; Therese M-L Andersson; Mark J Rutherford; Tor Åge Myklebust; Bjørn Møller
Journal:  Int J Epidemiol       Date:  2020-10-01       Impact factor: 7.196

Review 4.  Interpreting trends in cancer patient survival.

Authors:  P W Dickman; H-O Adami
Journal:  J Intern Med       Date:  2006-08       Impact factor: 8.989

5.  Progress in colorectal cancer survival in Europe from the late 1980s to the early 21st century: the EUROCARE study.

Authors:  Hermann Brenner; Anne Marie Bouvier; Roberto Foschi; Monika Hackl; Inger Kristin Larsen; Valery Lemmens; Lucia Mangone; Silvia Francisci
Journal:  Int J Cancer       Date:  2011-08-03       Impact factor: 7.396

6.  Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE--5-a population-based study.

Authors:  Roberta De Angelis; Milena Sant; Michel P Coleman; Silvia Francisci; Paolo Baili; Daniela Pierannunzio; Annalisa Trama; Otto Visser; Hermann Brenner; Eva Ardanaz; Magdalena Bielska-Lasota; Gerda Engholm; Alice Nennecke; Sabine Siesling; Franco Berrino; Riccardo Capocaccia
Journal:  Lancet Oncol       Date:  2013-12-05       Impact factor: 41.316

7.  Improved survival in cancer of the colon and rectum in Sweden.

Authors:  H Birgisson; M Talbäck; U Gunnarsson; L Påhlman; B Glimelius
Journal:  Eur J Surg Oncol       Date:  2005-10       Impact factor: 4.424

8.  Progress in cancer survival, mortality, and incidence in seven high-income countries 1995-2014 (ICBP SURVMARK-2): a population-based study.

Authors:  Melina Arnold; Mark J Rutherford; Aude Bardot; Jacques Ferlay; Therese M-L Andersson; Tor Åge Myklebust; Hanna Tervonen; Vicky Thursfield; David Ransom; Lorraine Shack; Ryan R Woods; Donna Turner; Suzanne Leonfellner; Susan Ryan; Nathalie Saint-Jacques; Prithwish De; Carol McClure; Agnihotram V Ramanakumar; Heather Stuart-Panko; Gerda Engholm; Paul M Walsh; Christopher Jackson; Sally Vernon; Eileen Morgan; Anna Gavin; David S Morrison; Dyfed W Huws; Geoff Porter; John Butler; Heather Bryant; David C Currow; Sara Hiom; D Max Parkin; Peter Sasieni; Paul C Lambert; Bjørn Møller; Isabelle Soerjomataram; Freddie Bray
Journal:  Lancet Oncol       Date:  2019-09-11       Impact factor: 41.316

9.  The loss in expectation of life after colon cancer: a population-based study.

Authors:  Therese M-L Andersson; Paul W Dickman; Sandra Eloranta; Annika Sjövall; Mats Lambe; Paul C Lambert
Journal:  BMC Cancer       Date:  2015-05-17       Impact factor: 4.430

10.  Estimating the change in life expectancy after a diagnosis of cancer among the Australian population.

Authors:  Peter D Baade; Danny R Youlden; Therese M-L Andersson; Philippa H Youl; Michael G Kimlin; Joanne F Aitken; Robert J Biggar
Journal:  BMJ Open       Date:  2015-04-13       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.